AdventHealth Orlando joins as newest trial site in pivotal Phase III trial
Tariq Awan, DO, a double-certified family and sports medicine physician with a special focus in sports medicine enters as GID BIO’s newest principal investigator in a pivotal Phase III trial evaluating cellular therapy for the treatment of pain and function as a result of knee osteoarthritis. He has served as team physician for the Detroit Red Wings and the University of Michigan’s men’s ice hockey team and is currently serving as a team physician for the Orlando Magic professional basketball team.
Dr. Awan heads a team of three physicians and other clinical support staff who lead the Central Florida site.
“We will investigate several areas, including the potential of cell-based therapy to slow disease progression, the impact of these cellular therapies on symptoms and the overall safety of using a person’s own adipose tissue to treat osteoarthritis. Symptom management for osteoarthritis is an important aspect of medicine because a person’s activity level has a positive impact on health and wellness,” noted Dr. Awan.
The team at AdventHealth Orlando joins seven sites including the University of California Davis School of Medicine, OrthoCarolina, and Wake Forest School of Medicine led by Charles De Mesa, DO, Claude T. Moorman, III, MD, and Neil Sparks, DO, MS, respectively.
For more information about the trial, visit clinicaltrials.gov.
Our cell therapy is not approved by the FDA for sale or use in the US.